Year : 2019  |  Volume : 21  |  Issue : 2  |  Page : 115-120

The current status of hormone treatment for prostate cancer patients in Korean real-world practice: a multi-institutional observational study

1 Department of Urology, Seoul National University Bundang Hospital, Seongnam 13620, Korea Department of Urology, Chonnam National University Hospital, Gwangju 61469, Korea School of Medicine, Kyungpook National University Medical Center, Daegu 41404, Korea Department of Urology, Konkuk University Medical Center, Seoul 05080, Korea Department of Urology, Wonkwang University Hospital, Iksan 54538, Korea Department of Urology, Daegu Catholic University Medical Center, Daegu 41911, Korea Department of Urology, Ulsan University, Gangneung Asan Hospital, Gangneung 25440, Korea Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea Department of Urology, Soonchunhyang University Hospital, Cheonan 31151, Korea Department of Urology, Hallym University Sacred Heart Hospital, Anyang 14068, Korea Department of Urology, Kangbuk Samsung Hospital, Seoul 03181, Korea Department of Urology, Seoul St. Mary Hospital, Seoul 06591, Korea ,

Correspondence Address:
Seok-Soo Byun
Department of Urology, Seoul National University Bundang Hospital, Seongnam 13620, Korea

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aja.aja_95_18

Rights and Permissions

We aimed to evaluate the current nationwide trend, efficacy, safety, and quality of life (QoL) profiles of hormone treatment in real-world practice settings for prostate cancer (PCa) patients in Korea. A total of 292 men with any biopsy-proven PCa (TanyNanyMany) from 12 institutions in Korea were included in this multi-institutional, observational study of prospectively collected data. All luteinizing hormone-releasing hormone (LHRH) agonists were allowed to be investigational drugs. Efficacy was defined as (1) the rate of castration (serum testosterone ≤50 ng dl−1) at 4-week visit and (2) breakthrough (serum testosterone >50 ng dl−1 after castration). Safety assessments included routine examinations for potential adverse events, laboratory tests, blood pressure, body weight, and bone mineral density (BMD, at baseline and at the last follow-up visit). QoL was assessed using the Expanded Prostate Cancer Index Composite-26 (EPIC-26). The most common initial therapeutic regimen was LHRH agonist with anti-androgen (78.0%), and the most commonly used LHRH agonist for combination and monotherapy was leuprolide (64.0% for combination and 58.0% for monotherapy). The castration and breakthrough rates were 78.4% and 6.6%, respectively. The laboratory results related to dyslipidemia worsened after 4 weeks of hormone treatment. In addition, the mean BMD T-score was significantly lower at the last follow-up (mean: −1.950) compared to baseline (mean: −0.195). The mean total EPIC-26 score decreased from 84.8 (standard deviation [s.d.]: 12.2) to 78.3 (s.d.: 8.1), with significant deterioration only in the urinary domain (mean: 23.5 at baseline and 21.9 at the 4-week visit). These findings demonstrate the nationwide trend of current practice settings in hormone treatment for PCa in Korea.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded519    
    Comments [Add]    
    Cited by others 1    

Recommend this journal